Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 534-545

  Lazarus, Hillard M ^a   Rowlings, Philip A ^a   Zhang, Mei Jie ^a   Vose, Julie M ^a   Armitage, James O ^a   Bierman, Philip J ^a   Gajewski, James L ^a   Gale, Robert Peter ^a   Keating, Armand ^a   Klein, John P ^a   Miller, Carole B ^a   Phillips, Gordon L ^a   Reece, Donna E ^a   Sobocinski, Kathleen A ^a   Van Besien, Koen ^a   Horowitz, Mary M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0033008436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.534     Document Type: Article

References (47)

1. De Vita VT Jr, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with chemotherapy. Ann Intern Med 92:587-595, 1980
2. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
3. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results. Ann Intern Med 104:739-746, 1986
4. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
5. Klimo P, Connors JM: An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 25:34-40, 1994
6. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992
7. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139-143, 1982
8. Buzaid AC, Lippman SM, Miller TP: Salvage therapy of advanced Hodgkin's disease: Critical appraisal of curative potential. Am J Med 83:523-532, 1987
9. Longo DL, Young RC, Wesley M, et al: Twenty years of Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
10. Harker WG, Kushlan P, Rosenberg SA: Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 101:440-446, 1984
11. Bonadonna G, Santoro A, Gianni AM, et al: Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol 2:9-16, 1991 (suppl 1)
12. Bergsagel DE: Salvage treatment for Hodgkin's disease in relapse. J Clin Oncol 5:525-526, 1987
13. Hagemeister FB, Tannir N, McLaughlin P, et al: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5:556-561, 1989
14. Schulman P, McCarroll K, Cooper MR, et al: Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: A CALGB study. Med Pediatr Oncol 18:482-486, 1990
15. Canellos GP: Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol 2:1-7, 1991
16. Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534, 1997
17. Brusamolino E, Orlandi E, Canevari A, et al: Results of CAV (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 5:427-432, 1994
18. Centers for Disease Control: National Hospital Discharge Survey for 1990 and 1991. Hyattsville, MD, National Center for Health Statistics, Hospital Care Statistics Branch, 1991
19. Graves EJ: Detailed diagnoses and procedures: National Hospital Discharge Survey, 1989. Vital Health Stat [13] 108:1-236, 1991
20. Mellor JA, Simmons AV, Bernard DL, et al: A retrospective evaluation of mediastinal tomograms, isotope liver scans and isotope bone scans in the staging and management of patients with lymphoma. Cancer 52:2227-2229, 1983
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
23. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997
24. Desablens B, Tourani JM, Casassus P, et al: Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbosplenic radiotherapy: The POF 81/12 protocol [French]. Presse Med 18:1917-1921, 1989
25. Burns LJ, Daniels KA, McGlave PB, et al: Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival. Bone Marrow Transplant 16:13-18, 1995
26. Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801-813, 1997
27. Yahalom J, Gulati SC, Toia M, et al: Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11:1062-1070, 1993
28. Chopra R, McMillan AK, Linch DC, et al: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center eight-year study of 155 patients. Blood 81:1137-1145, 1993
29. Reece DE, Barnett MJ, Connors JM, et al: Intensive chemotherapy with cyclophosphamide, carmustine, etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9:1871-1879, 1991
30. Ahmed T, Lake DE, Beer M, et al: Single and double autotransplants for relapsing/refractory Hodgkin's disease: Results of two consecutive trials. Bone Marrow Transplant 19:449-454, 1997
31. Carella AM, Congiu AM, Gaozza E, et al: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 6:1411-1416, 1988
32. Gribben JG, Linch DC, Singer CRJ, et al: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340-344, 1989
33. Bierman PJ, Vose JM, Armitage JO: Autologous transplantation for Hodgkin's disease: Coming of age? Blood 83:1161-1164, 1994
34. Reece DE, Barnett MJ, Shepherd JD, et al: High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451-456, 1995
35. Sweetenham JW, Taghipour G, Linch DC, et al: Thirty percent of adult patients with primary refractory Hodgkin's disease are progression free at 5 years after high dose therapy and autologous stem cell transplantation: Data from 290 patients reported to the EBMT. Blood 88:486a, 1996 (suppl 1, abstr #1932)
36. Prince HM, Crump M, Imrie K, et al: Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol 7:1043-1049, 1996
37. Rapoport AP, Rowe JM, Kouides PA, et al: One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351-2361, 1993
38. Crump M, Smith AM, Brandwein J, et al: High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 11:704-711, 1993
39. Reece DE, Connors JM, Spinelli JJ, et al: Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy, Blood 83:1193-1199, 1994
40. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11:2342-2350, 1993
41. Bierman PJ, Bagin RG, Jagannath S, et al: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients. Ann Oncol 4:767-773, 1993
42. Jagannath S, Armitage JO, Dicke KA, et al: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7:179-185, 1989
43. Armitage JO, Bierman PJ, Vose JM, et al: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 91:605-611, 1991
44. Nademanee A, O'Donnell MR, Snyder DS, et al: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381-1390, 1995
45. Hurd DD, Haake RJ, Lasky LC, et al: Treatment of refractory and relapsed Hodgkin's disease: Intensive chemotherapy and autologous peripheral blood stem cell support. Med Pediatr Oncol 18:447-453, 1990
46. Lumley MA, Milligan DW, Knechtli CJC, et al: High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease. Bone Marrow Transplant 17:383-388, 1996
47. Strauss DJ, Gaynor JJ, Myers J: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 7:1173-1181, 1990